1,721,788 research outputs found
Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system
Full text linkNo abstract availabl
Renal toxicity of anticancer agents targeting HER2 and EGFR
No full textEGFR and HER2 are found overexpressed and/or activated in many different human malignancies (e.g. breast and colon cancer), and a number of drugs specifically targeting these two tyrosine kinases have been developed over the years as anticancer agents. In the present review, the renal safety profile of presently available agents targeting either HER2 or EGFR will be discussed, together with the peculiarities related to their clinical use in patients with impaired renal function, or even in dialysis. Indeed, even though renal toxicity is not so common with these agents, it may nevertheless happen, especially when these agents are combined with traditional chemotherapeutic agents. As a whole, kidney impairment or dialysis should not be regarded per se as reasons not to administer or to stop an active anti-HER or anti-EGFR anticancer treatment, especially given the possibility of significantly improving the life expectancy of many cancer patients with the use of these agents
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Full text linknot availabl
ASSURE vs. S-TRAC: Conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics
Full text linkN
Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis
No full textNO ABSTRAC
[Interaction between respiration, autonomic function, and respiratory pattern in heart failure. New possibilities of rehabilitation intervention].
No full text
Urea-based cream to prevent sorafenib-induced hand-and-foot skin reaction: Which evidence?
No full textN
- …
